Eli Lilly’s powerful weight-loss drug Zepbound hit 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk’s rival obesity medicine Wegovy for the first time since it was launched, according to data from IQVIA. Some 6,000 fewer Wegovy prescriptions were filled in the United States that week, but Novo maintained its lead for total weekly prescriptions over Zepbound by 25,307, according to the data published by JPMorgan in a weekly note. Novo, Lilly and IQVIA did not immediately respond to requests for comment.
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...